Emerging disease modifying therapies for multiple sclerosis

Bibliography

• NOSEWORTHY JH, LUCCHINETTI C,RODRIGUEZ M, WEINSHENKER BG: Multiple sclerosis. N Engl..1. Med. (2000) 343:938–952.
   Google Scholar
• •Comprehensive review of MS and MS treatments.
   Google Scholar
• WEINSHENKER BG, BASS B, RICE GP et al: The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain (1989) 112:133–146.
   PubMed Web of Science ®Google Scholar
• LUBLIN FD, REINGOLD SC: Defining the clinical course of multiple sclerosis: results of an international survey. Neurology (1996) 46:907–911.
   PubMed Web of Science ®Google Scholar
• THOMPSON AJ, KERMODE AG, WICKS D et al.: Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann. Neurol (1991) 29:533–562.
   Google Scholar
• POSER CM, PATY DW, SCHEINBERG L et al.: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol (1983) 13:227–231.
   PubMed Web of Science ®Google Scholar
• MCDONALD WI, COMPSTON A, EDAN G et al.: Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol (2001) 50:121–127.
   PubMed Web of Science ®Google Scholar
• KERM ODE AG, THOMPSON AJ, TOFTS P et al.: Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain (1990) 113:1477–1489.
   PubMed Web of Science ®Google Scholar
• OKSENBERG JR, BARANZINI SE, BARCELLOS LF, HAUSER SL: Multiple sclerosis: genomic rewards. Neuroimmunol (2001) 113: 171–184.
   Google Scholar
• TRAPP BD, PETERSON J, RANSOHOFF RM, RUDICK R, MORK S, BO L: Axonal transection in the lesions of multiple sclerosis. N Engl I Med. (1998) 338:278–285.
   PubMed Web of Science ®Google Scholar
• LUCCHINETTI C, BRUCK W, PARISI J, SCHEITHAUER B, RODRIGUEZ M, LASSMANN H: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. (2000) 47(6):707–717.
   PubMed Web of Science ®Google Scholar
• ZAMVIL SS, STEINMAN L: The T lymphocyte in experimental allergic encephalomyelitis. (1990) Ann. Rev Immunol. 8:579–621.
   PubMed Web of Science ®Google Scholar
• GENAIN CP, CANNELLA B, HAUSER SL, RAINE CS: Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. (1999) 5(2):170–175.
   Google Scholar
• NO AUTHORS LISTED: Interferon beta-lb is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. IFNB Multiple Sclerosis Study Group. Neurology (1993) 43:655–661.
   PubMed Web of Science ®Google Scholar
• JACOBS LD, COOKFAIR D, RUDICK R et al.: Intramuscular interferon beta-la for disease progression in relapsing multiple sclerosis. Ann. Neurol (1996) 39:285–294.
   PubMed Web of Science ®Google Scholar
• JOHNSON KP, BROOKS BR, COHEN JA et al.: Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of a Phase III multicenter, double blind, placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology (1995) 45: 1268–1276.
   Google Scholar
• NO AUTHORS LISTED: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing remitting multiple sclerosis. PRISMS Study Group. Lancet (1998) 352: 1498–1504.
   Google Scholar
• HARTUNG HP, GONSETTE R, KONIG N et al.: Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet (2002) 360(9350):2018–2025.
   PubMed Web of Science ®Google Scholar
• YONG VW: Differential mechanisms ofaction of interferon-beta and glatiramer acetate in MS. Neurology (2002) 59:802–808.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Neurology (2001) 56: 1496–1504.
   Google Scholar
• COHEN JA, CUTTER GR, FISCHER JS et al.: Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology (2002) 59(5):679–687.
   Google Scholar
• JACOBS L, BECK R, SIMON J et al: Intramuscular interferon beta-la therapy initiated during a first demyelinating event in multiple sclerosis. N Engl. I Med. (2000) 343:898–904.
   PubMed Web of Science ®Google Scholar
• COMI G, FILIPPI M, BARKHOF F et al: Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet (2001) 357: 1576–1582.
   Google Scholar
• COMI G, FILIPPI M, WOLINSKY JS et al.: European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effect of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol (2001) 49: 290–297.
   Google Scholar
• ANDERSSON PB, GOODKIN DE: Glucocorticosteroid therapy for multiple sclerosis: a critical review. I Neurol. ScL (1998) 160(1):16–25.
   Google Scholar
• GOODKIN DE, KINKEL RP, WEINSTOCK-GUTTMAN B et al.: A Phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology(1998) 51(1):239–245.
   Google Scholar
• ZIVADINOV R, RUDICK RA, DE MASI R et al.: Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology (2001) 57(7):1239–1247.
   Google Scholar
• RIDGE SC, SLOBODA AE, MCREYNOLDS RA et al.: Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clio. Immunol Immunopathol (1985) 35:35–42.
   PubMed Web of Science ®Google Scholar
• HAUSER SL, DAWSON DM, LEHRICH JR et al.: Intensive immunosuppression in progressive multiple sclerosis; a randomised, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl. Med. (1983) 308: 173–180.
   Google Scholar
• NO AUTHORS LISTED: The Canadian co-operative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Canadian Cooperative Multiple Sclerosis Study Group. Lancet (1991) 337:441–446.
   PubMed Web of Science ®Google Scholar
• WEINER H, MACKIN G, ORAV E et al: Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology (1993) 43:910–918.
   PubMed Web of Science ®Google Scholar
• SMITH DR, WEINSTOK- GUTTMAN B, COHEN J et al.: Randomized trial of pulse cyclophosphamide in IFNB resistant active MS. Neurology (2002) 58 (Suppl. 3):A455.
   Google Scholar
• GOODKIN DE, BAILY RC, TEETZEN ML, HERTSGAARD D, BEATTY WW: The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology (1991) 41:20–25.
   PubMed Web of Science ®Google Scholar
• YUDKIN PL, ELLSION GW, GHEZZI A et al.: Overview of azathioprine treatment in multiple sclerosis. Lancet (1991) 338: 1051–1055.
   Google Scholar
• PALACE J, ROTHWELL P: New treatments and azathioprine in multiple sclerosis. Lancet (1997) 350:261.
   PubMed Web of Science ®Google Scholar
• CAVAZZUTI M, MERELLI E, TASSONE G, MAVILLA L: Lesion load quantification in serial MR of early relapsing multiple sclerosis patients in azathioprine treatment. A retrospective study. Eur. Neurol. (1997) 38(4):284–290.
   PubMed Web of Science ®Google Scholar
• GOODKIN DE, RUDICK RA, VANDERBRUG MEDENDORP S et al Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann. Neurol (1995) 37(1):30–40.
   PubMed Web of Science ®Google Scholar
• GOODKIN DE, RUDICK RA, VANDERBRUG MEDENDORP S, DAUGHTRY MM, VAN DYKE CD: Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRFs. Neurology(1996) 47: 1153–1157.
   Google Scholar
• FAZEKAS F, DEISENHAMMER F, STRASSER-FUCHS S, NAHLER G, MAMOLI B: Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet (1997) 349:589–593.
   PubMed Web of Science ®Google Scholar
• ACHIRON A, GABBAY U, GILAD R et al.: Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology (1998) 50:398–402.
   PubMed Web of Science ®Google Scholar
• WEINSHENKER BG, O'BRIEN PC, PETTERSON PM et al: A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann. Nemo]. (1999) 46:878–886.
   PubMed Web of Science ®Google Scholar
• HOHLFELD R: Biotechnical agents for theimmunotherapy of MS: principles, problems and perspectives. Brain (1997) 120:865–916.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of emerging therapies for MS.
   Google Scholar
• SMITH T, GROOM A, ZHU B, TURSKI L: Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med (2000) 6:62–66.
   PubMed Web of Science ®Google Scholar
• PITT D, WERNER P, RAINE C: Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med (2000) 6:67–70.
   PubMed Web of Science ®Google Scholar
• WERNER P, PITT D, RAINE C: Multiplesclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann. Neurol (2001) 50:169–180.
   PubMed Web of Science ®Google Scholar
• CHANG A, TOURTELLOTTE WW, RUDICK R, TRAPP BD: Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engi J. Med. (2002) 346(3):165–173.
   PubMed Web of Science ®Google Scholar
• LEARY SM, MILLER DH, STEVENSON VL, BREX PA, CHARD DT, THOMPSON AJ: Interferon beta-la in primary progressive MS. An exploratory, randomized, controlled trial. Neurology (2003) 60:44–51.
   PubMed Web of Science ®Google Scholar
• MANDALFINO P, RICE G, SMITH A, KLEIN JL, RYSTEDT L, EBERS GC: Bone marrow transplantation in multiple sclerosis.' Neurol (2000) 247(9):691–695.
   Web of Science ®Google Scholar
• FASSAS A, PASSWEG JR, ANAGNOSTOPOULOS A et al.: Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.' Neurol. (2002) 249(8):1088–1097.
   Web of Science ®Google Scholar
• CAO L, SUN D, CRUZ T, MOSCARELLO MA, LUDWIN SK, WHITAKER JN: Inhibition of experimental allergic encephalomyelitis in the Lewis rat by paclitaxel. Neuroimmunoi (2000) 108(1-2):103–111.
   PubMed Web of Science ®Google Scholar
• JACOBSOHN DA: Novel therapeutics forthe treatment of graft-versus-host disease. Expert Opin. Investig. Drugs (2002) 11(9):1271–1280.
   PubMed Web of Science ®Google Scholar
• BIELEKOVA B, MARTIN R: Antigen-specific immunomodulation via altered peptide ligands.j. Ma Med (2001) 79(10):552–565.
   Google Scholar
• GENAIN CP, ZAMVIL SS: Specific immunotherapy: one size does not fit all. Nat. Med. (2000) 6(10):1098–1100.
   PubMed Web of Science ®Google Scholar
• BIELEKOVA B, GOODWIN B, RICHERT N et al.: Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a Phase II clinical trial with an altered peptide ligand. Nat. Med. (2000) 6:1167–1175.
   PubMed Web of Science ®Google Scholar
• KAPPOS L, COMI G, PANITCH H et al:Induction of a non-encephalitogenic Type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized Phase II trial. Nat. Med. (2000) 6:1176–1182.
   PubMed Web of Science ®Google Scholar
• KIM H, ANTEL J, DUQUETTE P, ALLEVA DG, CONLON PJ, BAR-OR A: Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand. Clio. Immunoi (2002) 104:105–114.
   PubMed Web of Science ®Google Scholar
• BEN-NUN A, WEKERLE H, COHEN IR: Vaccination against autoimmune encephalomyelitis with T-lymphocytes cell lines reactive against myelin basic protein. Nature (1981) 292:60–61.
   PubMed Web of Science ®Google Scholar
• ZHANG J, MEDAER R, STINISSEN P, HAFLER D, RAUS J: MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science (1993) 261:1451–1454.
   PubMed Web of Science ®Google Scholar
• MEDAER R, STINISSEN P, TRUYEN L, RAUS J, ZHANG J: Depletion of myelin-basic-protein-autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis. Lancet (1995) 346:807–808.
   PubMed Web of Science ®Google Scholar
• CORREALE J, LUND B, MCMILLAN M, KO DY, MCCARTHY K, WEINER LP: T cell vaccination in secondary progressive multiple sclerosis. Neuroimmunoi (2000) 107(2):130–139.
   PubMed Web of Science ®Google Scholar
• VANDENBARK AA, CHOU YK, WITHAM R et al. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat. Med. (1996) 2:1109–1115.
   PubMed Web of Science ®Google Scholar
• BOURDETTE DN, CHOU YK, WHITHAM RH et al.: Immunity to T cell receptor peptides in multiple sclerosis. III. Preferential immunogenicity of complementarity-determining region 2 peptides from disease-associated T cell receptor BV genes. Immunol (1998) 161(2):1034–1044.
   Web of Science ®Google Scholar
• MORGAN EE, NARDO CJ, DIVELEY JP et al.: Vaccination with a CDR2 BV652/ 6S5 peptide in adjuvant induces peptide-specific T-cell responses in patients with multiple sclerosis. Neurosci. Res. (2001) 64(3):298–301.
   Web of Science ®Google Scholar
• KOTZIN BL, KARUTURI S, CHOU YK et al.: Preferential T cell receptor I3-chain variable gene use in myelin basic protein-reactive T cell clones from patients with multiple sclerosis. Proc. Nati Acad. Sci. USA (1991) 88:9161–9165.
   PubMed Web of Science ®Google Scholar
• CROSS AH, GIRARD TJ, GIACOLETTO KS et al.: Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. Clin. Invest. (1995) 95:2783–2789.
   Google Scholar
• KHOURY SJ, AKALIN E, CHANDRAKER A et al: CD28-B7 costimulatory blockade by CTLA-4 Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Thl but spares Th2 cytokines in the central nervous system. Immunoi (1995) 155(10):4521–4524.
   PubMed Web of Science ®Google Scholar
• HOWARD LM, MIGA AJ, VANDERLUGT CL et al.: Mechanisms of immunotherapeutic intervention by anti-CD4OL (CD154) antibody in an animal model of multiple sclerosis. Clio. Invest. (1999) 103(2):281–290
   PubMed Web of Science ®Google Scholar
• MOREAU T, THORPE J, MILLER D et al.: Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet (1994) 344:298–301.
   PubMed Web of Science ®Google Scholar
• MOREAU T, COLES A, WING M et al.:Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain (1996) 119:225–237.
   PubMed Web of Science ®Google Scholar
• ELLIS CN, KRUEGER GG: Treatment ofchronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl. J. Med. (2001) 345(4):248–255.
   PubMed Web of Science ®Google Scholar
• TREBST C, SORENSEN TL, KIVISAKK P et al: CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am. J. Pathol. (2001) 159:1701–1710.
   PubMed Web of Science ®Google Scholar
• ROTTMAN JB, SLAVIN AJ, SILVA R, WEINER HL, GERARD OG, HANCOCK WW: Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur.j Immunol (2000) 30(8):2372–2377.
   PubMed Web of Science ®Google Scholar
• KWAK B, MULHAUPT F, MYIT S, MACH F: Statins as a newly recognized type of immunomodulator. Nat. Med. (2000) 6(12):1399–1402.
   PubMed Web of Science ®Google Scholar
• WEITZ-SCHMIDT G, WELZENBACH K, BRINKMANN V et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. (2001) 7(6):687–692.
   PubMed Web of Science ®Google Scholar
• PAHAN K, SHEIKH FG, NAMBOODIRI AM, SINGH I: Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clio. Invest. (1997) 100:2671–2679.
   PubMed Web of Science ®Google Scholar
• YOUSSEF S, STUVE O, PATARROYO JC et al.: The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in CNS autoimmune disease. Nature (2002) 420(6911):78–84.
   PubMed Web of Science ®Google Scholar
• VOLLMER T, DURKALSKI V, TYOR W et al.: An open-label, single arm study of simvastatin as a therapy for multiple sclerosis. Neurology (2003) 60\(Suppl. 1):A84.
   Web of Science ®Google Scholar
• JANSSON L, OLSSON T, HOLMDAHL R: Estrogen induces a potent suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis in mice. Neuroimmunol. (1994) 53:203–207.
   PubMedGoogle Scholar
• BEBO BF, FYFE-JOHNSON A, ADLARD K, BEAM AG, VANDENBARK AA, OFFNER H: Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. Immunol (2001) 166:2080–2089.
   Web of Science ®Google Scholar
• SICOTTE N, PFIEFFER P, KLUTCH R et al.: Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann. Neurol (2002) 52(4):421–428.
   PubMed Web of Science ®Google Scholar
• SOOS JM, SUBRAMIAN PS, HOBEIKA AC, SCHIFFENBAUER J, JOHNSON HM: The interferon pregnancy recognition hormone, interferon tau, blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity. Immunol (1995) 155:2747–2753.
   Web of Science ®Google Scholar
• SOOS JM, MUSTAFA GM, SUBRAMANIAN PS, STREIT WJ, JOHNSON HJ: Oral feeding of interferon 'c can prevent acute and chronic relapsing forms of experimental allergic encephalomyelitis. Neuroimmunol. (1997) 75:43–50.
   PubMed Web of Science ®Google Scholar
• OLEK MJ, SMITH DJ, COOK SL, KHOURY SJ, WEINER HL: Phase I study of oral recombinant ovine interferon-tau in relapsing-remitting multiple sclerosis. Neurology (2001) 56\(Suppl. 3):A76.
   Google Scholar
• GENAIN CP, ROBERTS T, DAVIS RL et al.: Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. USA (1995) 92(8):3601–3605.
   PubMed Web of Science ®Google Scholar
• FOLCIK VA, SMITH T, O'BRYANT S et al.: Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of Type IV phosphodiesterase inhibitors. J.Neuroimmunol. (1999) 97(1-2):119–128.
   PubMed Web of Science ®Google Scholar
• LYONS JA, SAN M, HAPP MP, CROSS AH: B-cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur. I Immunol (1999) 29:3432–3439.
   PubMed Web of Science ®Google Scholar
• YEDNOCK TA, CANNON C, FRITZ LC, SANCHEZ-MADRID F, STEINMAN L, KARIN N: Prevention of experimental autoimmune encephalomyelitis by antibodies against a431 integrin. Nature (1992) 356:63–66.
   PubMed Web of Science ®Google Scholar
• MILLER DH, KHAN OA, SHEREMATA WA et al.: A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl. J. Med. (2003) 348(1):15–23.
   PubMed Web of Science ®Google Scholar
• CLEMENTS JM, COSSINS JA, WELLS GMA et al: Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effect of a combined matrix metalloproteinase and tumor necrosis factor-alpha inhibitor. Neuroimmunol (1997) 74:85–94.
   PubMed Web of Science ®Google Scholar
• MARRACCI GH, JONES RE, MCKEON GP, BOURDETTE DN: Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J. Neuroimmunol. (2002) 131(1-2):104–114.
   PubMed Web of Science ®Google Scholar
• BRUNDULA V, REWCASTLE NB, METZ LM, BERNARD CC, YONG VW: Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brad) (2002) 125:1297–1308.
   Google Scholar
• POPOVIC N, SCHUBART A, GOETZ BD, ZHANG SC, LININGTON C, DUNCAN ID: Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann. Neurol (2002) 51(2):215–223.
   PubMed Web of Science ®Google Scholar
• ZHU S, STAVROVSKAYA IG, DROZDA M et al.: Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature (2002) 417:74–78.
   PubMed Web of Science ®Google Scholar
• METZ LM, YONG VW, YEUNG M et al.: Open-label trial of minocycline in active relapsing-remitting multiple sclerosis. Neurology (2003) 60\(Suppl. 1):A250.
   Google Scholar
• GUO X, DILLMAN JF 3RD, DAWSON VL, DAWSON TM: Neuroimmunophilins: novel neuroprotective and neuroregenerative targets. Ann. Neurol (2001) 50(1):6–16.
   PubMed Web of Science ®Google Scholar
• KURTZKE JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (1983) 33:1444–1452.
   PubMed Web of Science ®Google Scholar
• KALKERS NE BARKHOF F, BERGERS E, VAN SCHIJNDEL R, POLMAN CH: The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult. Scler: (2002) 8(6):532–533.
   PubMed Web of Science ®Google Scholar